working

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here

More Content

More Content

OSE Immunotherapeutics:Bridge equity financing to extend runway

Companies: Ose Immunotherapeutics (OSE:EPA)OSE Immunotherapeutics SA (OSE:PAR)

OSE Immunotherapeutics - executive interview

Companies: OSE Immunotherapeutics SA

OSE Immunotherapeutics:Positive Tedopi combination data in OC

Companies: Ose Immunotherapeutics (OSE:EPA)OSE Immunotherapeutics SA (OSE:PAR)

OSE Immunotherapeutics – executive interview with Nicolas Poirier, CEO

Companies: OSE Immunotherapeutics SA

OSE Immunotherapeutics:All on track following FY25 and Q126 updates

Companies: Ose Immunotherapeutics (OSE:EPA)OSE Immunotherapeutics SA (OSE:PAR)

© Research Tree 2026

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top